GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- B1180 S1RA hydrochlorideSummary: σ1R antagonist
- B2214 ValsartanTarget: Angiotensin AT1 ReceptorsSummary: Angiotensin II AT1 receptor antagonist
- B1465 Plerixafor 8HCl (AMD3100 8HCl)Target: CXCRSummary: CXCR4 antagonist
- B1423 Cinacalcet HClSummary: Calcium-sensing receptor (CaR) agonist
- B2163 SB408124Summary: OX(1)receptor antagonist
- B2237 Eletriptan HBrSummary: selective 5-HT1B and 5-HT1D receptor agonist
- B1682 BosentanSummary: Endothelin receptor antagonist
- B1521 Bosentan HydrateSummary: endothelin receptor antagonist
- B2229 Palonosetron HClSummary: 5-HT receptor antagonist
- B1754 Fenspiride HClSummary: α adrenergic and H1 histamine receptor antagonist